Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

NCT05694364 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Acute Lymphoblastic Leukemia
Diffuse Large B Cell Lymphoma
Triple Negative Breast Cancer Malignancies

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: PRGN-3007

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]